Indications
Therapeutic Asset Ratings
3,186 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
a2b543
Colorectal Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(40)
a2b543
Ovarian Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(40)
a2b694
Colorectal Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(40)
a2b694
Ovarian Cancer
A2 Biotherapeutics Inc.
P1/2
CC
(40)
Afnt-211
Colorectal Cancer
Affini-T Therapeutics, Inc.
P1/2
CC
(40)
Afnt-211
Non-Small Cell Lung Carcinoma
Affini-T Therapeutics, Inc.
P1/2
CC
(40)
Afnt-211
Neoplasm
Affini-T Therapeutics, Inc.
P1/2
CC
(40)
Allogeneic Adipose-Derived Mesenchymal Stem Cells
Prostate Cancer
The Methodist Hospital Research Institute
P1/2
CC
(40)
Allogeneic Tcr-Enhanced Vδ2 T Cell
Neoplasm
Chinese PLA General Hospital
P1/2
CC
(40)
Amt-116 Car-T Cells
Non-Small Cell Lung Carcinoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(40)
Amt-253 Car-T Cells
Non-Small Cell Lung Carcinoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(40)
Anti-Fcrl5 Car-T
Plasma Cell Myeloma
Xuzhou Medical University
P1/2
CC
(40)
Anti-Flt3 Car-T
Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
P1/2
CC
(40)
Anti-Hcd70 Car Transduced Pbl
Breast Cancer
National Cancer Institute (NCI)
P1/2
CC
(40)
Anti-Hcd70 Car Transduced Pbl
Ovarian Cancer
National Cancer Institute (NCI)
P1/2
CC
(40)
Anti-Hcd70 Car Transduced Pbl
Pancreatic Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(40)
Anti-Kras G12V Mtcr Pbl
Pancreatic Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(40)
Anti-Mesothelin Chimeric T Cell Receptor Transduced Peripheral Blood Lymphocytes
Ovarian Cancer
Weijia Fang, MD
P1/2
CC
(40)
Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
Cancer
T-knife GmbH
P1/2
CC
(40)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Neoplasm
Rapa Therapeutics LLC
P1/2
CC
(40)
bc1 cell line
Breast Cancer
BriaCell Therapeutics Corporation
P1/2
CC
(40)
B-Cell Maturation Antigen Directed Chimeric Antigen Receptor -T Cell
Plasma Cell Myeloma
Bioray Laboratories
P1/2
CC
(40)
Bcma/Gprc5D Car-T Cells
Plasma Cell Myeloma
Essen Biotech
P1/2
CC
(40)
Bcma Targeted Prime Car-T Cells
Plasma Cell Myeloma
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(40)
bi-4scar gd2/psma t cells
Neoplasm
Shenzhen Geno-Immune Medical Institute
P1/2
CC
(40)
Showing 2176 to 2200 of 3,186 assets
Previous
Page 88 of 128
Next
